Authors
Latest:
America’s Opioid Crisis: Potential Increased Regulation of MarketingWith over 70 companies manufacturing immediate-release opioids in the United States, federal regulators may look to limit, or at least impose greater control over, marketing as a strategy to reduce the prescription, and more specifically, the improper and/or over-prescription of opioids.
Latest:
Drug Delivery’s Role in Improving Rural OutcomesIn the search for effective and efficient ways to bridge the urban/rural divide, technological advances are offering more and more solutions.
Latest:
Best Practices For Building Scalable R&D Data PlatformsThis article discusses the best practices for transforming legacy approaches of managing data into modern ones capable of achieving the ambitious visions of pharmaceutical companies.
Latest:
Olivier Laureau, Servier: Free to Grow, InnovateFrench independent pharma Servier Group, led by president Olivier Laureau, is uniquely positioned to capitalize on new opportunities for expansion and stay true to its R&D and patient-focused mission.
Latest:
From Lab to Life: Improving Patient Lives through Community-based Healthcare and Decentralized Clinical TrialsIn Episode Three of the Syneos Health Dedicated Dialogue podcast series, we uncover how the proliferation of new digital health technologies, telemedicine and mobile nursing services are helping fuel novel clinical trials. These range from community-based studies, which are administered through PCPs, local health centers and outpatient facilities in lieu of academic research centers, to hybrid and fully virtual trials designed around patients in their homes, with or without a synthetic control arm replacing patients on placebos. Additionally, we share new insights about how trial sponsors discovering new ways to engage participants, enhance data capture and devise pathways to put patients at the center of clinical trials across the biopharmaceutical product development continuum.
Latest:
Compliance Information at a ClickTracy Rockney and Rob Merrill talk about their free regulatory compliance and information platform MyIndago, and why they think the industry needs it now.
Latest:
Master Data Management 2.0Using intelligent automation of content creation can turn master product data into business value, writes Siniša Belina.
Latest:
The Top Barriers to Patient PersistenceAnd ways pharma can help overcome these hurdles-and boost compliance rates across the full durations of treatment
Latest:
AI in the Medical Domain: Not a Quick FixDanish Gupta discuss the current strengths and weaknesses of artificial intelligence applications in life sciences.
Latest:
Spotlight on Mexico: Healthcare under AMLO—One Year OnAs we near the end of the first year of Mexican president Andrés Manuel López Obrador's six-year term, Rachel Howard caught up with local expert Dr Xavier Tello to make sense of the latest changes in the healthcare system and consider what they mean for pharma manufacturers wishing to enter the Mexican market.
Latest:
Revolutionizing Clinical Trials Through Real-Time Data Capture and AnalyticsThis article discusses real-time data capture and analytics in clinical trials.
Latest:
Revolutionizing Clinical Trials Through Real-Time Data Capture and AnalyticsThis article discusses real-time data capture and analytics in clinical trials.
Latest:
Revolutionizing Clinical Trials Through Real-Time Data Capture and AnalyticsThis article discusses real-time data capture and analytics in clinical trials.
Latest:
Asembia 2018 Insights: Consolidation Madness, Carrots and SticksCurant Health executive discusses key insights from Asembia 2018.
Latest:
Compliance in China: Key ConsiderationsDavid Simon outlines the procedures to manage anti-corruption risk that life sciences companies should consider before doing business in China.
Latest:
Healthcare Reform in Ukraine Opens New Horizons for InvestorsAs the Ukranian healthcare market opens up to more public and private competition, it will become more attractive for investors - both Ukrainian and foreign, write Lana Sinichkina and Anna Zorya.
Latest:
Listening Is the Key to Becoming More Than Just Better MarketersBut how much better would our creative be if we took the time to really listen to what our clients are saying – and what they are not saying – rather than reading between the lines of an RFP?
Latest:
The Call for Further Advancement of Indication-Based PricingPayers and pharma must shift away from the traditional one drug–one price approach and expand "indication-based pricing", writes Anaïs Frappé.
Latest:
CRO Trends 2018Improving the productivity of sponsors’ clinical development processes will continue to be a primary driver of outsourcing in 2018, writes Nuala Murphy.
Latest:
Addressing the Security Challenges Facing Life Sciences and Healthcare CompaniesAchieving proper security in industries like life sciences and healthcare, where web-based systems and internal networks are late in coming, may seem a daunting task. But it shouldn't be, writes Dr. JeffR. Livingstone.
Latest:
Three Facets of Trust in Artificial IntelligenceAre the technologies and assumptions at the heart of healthcare AI trustworthy?
Latest:
The PD-1 Race in China Heats UpBoth foreign and domestic pharmas are in a race to bring PD-1/PD-L1 inhibitors into China, writes Jin Zhang.
